HeartBeam reports Q1 EPS (12c) vs. (18c) last year

“In just two months since our last earnings call, we made significant progress executing against the commercialization and growth strategy we’ve consistently discussed over the last several quarters. We established flagship commercial accounts across New York, Dallas, South Florida and Southern California, advanced our heart attack detection and on-demand 12-lead patch initiatives, and strengthened our balance sheet. HeartBeam’s (BEAT) differentiated FDA-cleared synthesized 12-lead ECG platform remains the foundation of our growth, backed by strong IP and clinical evidence,” said Robert Eno, Chief Executive Officer, HeartBeam. “Looking ahead, we remain focused on expanding our commercial footprint by driving deep adoption within our flagship accounts and continuing to build out workflow integration and patient onboarding within those practices while continuing to make significant advancements with our patch, heart attack detection and AI initiatives throughout 2026.”